This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.

Dev

Joined: October 9, 2025
Articles: 6278

JPND News

Additional 23m investment to analyse common pathways and develop new ideas on preventive strategies for neurodegenerative diseases

JPND has launched two calls for proposals aimed at encouraging research teams across Europe to investigate the cross-disease pathways in neurodegenerative diseases such as Alzheimers and Parkinsons, and to identify new, innovative preventive strategies for these debilitating conditions. Neurodegenerative Diseases…

Dev
December 2, 2013

press-article

December 2013 The Lancet Neurology Editorial

The Lancet Neurology Editorial

Dev
December 1, 2013

Research News (General)

Second amyloid imaging agent approved in US. EU approval submitted

The U.S. Food and Drug Administration on October 25 approved a second amyloid imaging agent. Flutemetamol is an F18-labeled ligand developed by GE Healthcare. It joins florbetapir, developed by Avid Pharmaceuticals/Eli Lilly and Company. Flutemetamol differs slightly from its cousin…

Dev
November 22, 2013

JPND News

Winter 2013 JPND Newsletter

The JPND Newsletter brings together a number of relevant JPND news stories for JPND international stakeholder communities. Contents include highlights of JPND activities, information on JPND-supported projects as well as interviews with JPND Scientific Advisory Board members. The second edition (November 2013) is…

Dev
November 19, 2013

Research News (General)

More Evidence for AD Starting Without Brain Amyloid

Researchers studying the natural history of Alzheimers disease are grappling with a puzzling group of volunteersamyloid-free and cognitively normal older adults who show other biomarker evidence of neurodegeneration. Researchers studying the natural history of Alzheimers disease are grappling with a…

Dev
November 18, 2013

views

Thomas Gasser – Chair of JPND SAB

You have been studying Parkinson’s for over 20 years. What is your working hypothesis of what causes this disease? The past 20 years have seen remarkable progress in our understanding of the causes of Parkinson’s disease. This progress has mostly…

Dev
November 15, 2013

views

Brian Fiske – SAB member – The Michael J. Fox Foundation for Parkinson’s Research

In your opinion, what is the single biggest challenge for researchers investigating neurodegenerative disorders? Parkinson’s disease is complex but we’re learning a lot about its possible causes and underlying biology and this, in turn, is feeding a robust therapeutic pipeline.…

Dev
November 12, 2013

views

Francois Nicolas – former SAB member

JPND Scientific Advisory Board Member (2013-2014) – representative of GE Healthcare It is widely acknowledged that we need new diagnostic solutions to identify Alzheimer’s patients, in particular those in the early stages of the disease. You are in charge…

Dev
November 11, 2013

JPND News

JPND Partnering Tool now available

JPND is piloting an online partnering tool as an optional support for researchers interested in responding to the 2013 JPND Annual Calls for proposals. Two JPND Calls for proposals are due to launch in early December, with the indicative call titles…

Dev
November 6, 2013

press-article

November 2013 Digital Journal

Digital Journal

Dev
November 1, 2013

Post

Post